A novel BTK inhibitor BGB-3111: new data presented at ASH 2017

Constantine Tam

Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.

Share this video  
Similar topics
Related videos
3:56
Can the dream of affordable cancer care come true?
Paul Cornes
4:21
ASH 2017 update on progress with novel AML treatments at MD Anderson
Naval Daver et al.
1:47
Combating AML
Andrew Wei
4:18
Brewing T-cell therapies for leukemia and lymphoma
David Maloney
1:47
CAR T-cell development in Europe – where are we in CLL?
John Gribben
Chronic Lymphocytic Leukemia
BGB-3111, Zanubrutinib
ASH 2017
Interview
More from Constantine Tam
New therapeutic targets in CLL: ROR1
Panel discussion on mantle cell lymphoma
Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals